文献速递胸部肿瘤放疗消化道肿瘤放疗放疗物理与技术

基于CT的Delta放射组学列线图鉴别食管癌放疗后放射性肺炎

Computed Tomography-Based Delta-Radiomics Analysis for Discriminating Radiation Pneumonitis in Patients With Esophageal Cancer After Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-05-08

PURPOSE: Our purpose was to construct a computed tomography (CT)-based delta-radiomics nomogram and corresponding risk classification system for individualized and accurate estimation of severe acute radiation pneumonitis (SARP) in patients with esophageal cancer (EC) after radia…

要点

  • 基于CT1至CT2的delta放射组学特征与重度急性放射性肺炎显著相关(P<.001)。
  • 整合delta放射组学特征与主观整体评估评分、肺纤维化评分、平均肺剂量及系统免疫炎症指数的列线图预测准确性提高。
  • 列线图在训练集和验证集C指数分别为0.975和0.921,校准曲线与决策曲线分析确认临床可行性。

核心结论

  • 基于CT的delta放射组学列线图及风险分类系统能以低成本、无创方式为食管癌患者提供个体化重度急性放射性肺炎分层概率。

研究设计与样本

  • 采用LASSO算法筛选特征并构建delta放射组学标签,结合多因素分析建立列线图,用C指数、校准曲线和决策曲线分析评估,并用递归分割分析生成风险分类系统。

主要发现

  • 由24个特征组成的delta放射组学标签与重度急性放射性肺炎状态显著相关(P<.001)。
  • 整合delta放射组学标签与主观整体评估评分、肺纤维化评分、平均肺剂量及系统免疫炎症指数的列线图,在训练集和验证集的C指数分别为0.975和0.921。
  • 校准曲线和决策曲线分析证实列线图具有满意的临床可行性和实用性。
  • 风险分类系统在识别重度急性放射性肺炎发生方面表现优异(P<.001)。

关键数值与推荐

  • delta放射组学标签包含24个特征。
  • 列线图整合的预测因子包括主观整体评估评分、肺纤维化评分、平均肺剂量和系统免疫炎症指数。
  • 训练集C指数0.975,验证集C指数0.921。
  • delta放射组学标签与重度急性放射性肺炎状态相关P<.001;风险分类系统识别重度急性放射性肺炎P<.001。

临床怎么用

  • 可利用放疗前和40-45Gy时CT提取的delta放射组学特征,结合临床、剂量和血液学指标,个体化评估食管癌患者重度急性放射性肺炎风险。
  • 列线图可辅助识别高危患者并进行风险分层,以支持临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our purpose was to construct a computed tomography (CT)-based delta-radiomics nomogram and corresponding risk classification system for individualized and accurate estimation of severe acute radiation pneumonitis (SARP) in patients with esophageal cancer (EC) after radiation therapy. METHODS AND MATERIALS: Four hundred patients with EC were enrolled from 2 independent institutions and were divided into the training (n = 200) and validation (n = 200) cohorts. Eight hundred fifty radiomics features of lung were extracted from treatment planning images, including the positioning CT before radiation therapy (CT1) and the resetting CT after receiving 40 to 45 Gy (CT2). The longitudinal net changes in radiomics features from CT1 to CT2 were calculated and defined as delta-radiomics features. Least absolute shrinkage and selection operator algorithm was performed to features selection and delta-radiomics signature building. Integrating the signature with multidimensional clinicopathologic, dosimetric, and hematological predictors of SARP, a novel CT-based delta-radiomics nomogram was established according to multivariate analysis. The clinical application values of nomogram were both evaluated in the training and validation cohorts by concordance index, calibration curves, and decision curve analysis. Recursive partitioning analysis was used to generate a risk classification system. RESULTS: The delta-radiomics signature consisting of 24 features was significantly associated with SARP status (P < .001). Incorporating it with other high-risk factors, Subjective Global Assessment score, pulmonary fibrosis score, mean lung dose, and systemic immune inflammation index, the developed delta-radiomics nomogram showed increased improvement in SARP discrimination accuracy with concordance index of 0.975 and 0.921 in the training and validation cohorts, respectively. Calibration curves and decision curve analysis confirmed the satisfactory clinical feasibility and utility of nomogram. The risk classification system displayed excellent performance on identifying SARP occurrence (P < .001). CONCLUSIONS: The delta-radiomics nomogram and risk classification system as low-cost and noninvasive means exhibited superior predictive accuracy and provided individualized probability of SARP stratification for patients with EC.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Wang L, Gao Z, Li C, et al. Computed Tomography-Based Delta-Radiomics Analysis for Discriminating Radiation Pneumonitis in Patients With Esophageal Cancer After Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021. PMID: 33974887. doi:10.1016/j.ijrobp.2021.04.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。